Komori
Results2158FRONTEO,Inc.Information and Communications, Services and Others

Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 (Japanese GAAP) (Consolidated)

For the interim period of the fiscal year ending March 2027, net sales declined 2.5% year on year, while the operating loss widened significantly from ¥7.7 million to ¥244.2 million. The full-year earnings and dividend forecasts remain unchanged, with higher earnings and a return to profitability expected in the second half.

Worth reading
67In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
236548
Thousand yen
Wording
Conditional
How definitive the wording is.

Results for this period

Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAP
Net Sales3,292¥ millionYear on year -2.5%Progress 43.3%
Operating profit-244¥ million
Ordinary income-229¥ million
Net income attributable to owners of the parent-186¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share-¥4.77
Financial position at period-end
Total assets8,761¥ million
of which net assets 3,645 ¥ millionEquity ratio 39.5%vs. prior year-end -0.2pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating-135,573
Investment-482,966
Financials+152,613
Net change-465,926

Stacked from zero: upward is an increase in cash, downward a decrease (in Thousand yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period1,257,541 Thousand yen
Segment revenueLife Science AI business 384,496 Thousand yen (YoY +40.3%), Risk management business 1,539,456 Thousand yen (YoY -24.2%), DX business 1,429,219 Thousand yen (YoY +32.7%)
Segment profitLife Science AI business -149,455 Thousand yen, Risk management business -114,388 Thousand yen, DX business 68,934 Thousand yen (YoY +48.8%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥7,600 million (YoY -0.6%)
Operating profit¥300 million (YoY -59.4%)
Ordinary income¥250 million (YoY -63.0%)
Net income¥150 million (YoY -72.4%)
Annual Dividend Forecast0 Yen → 0 Yen(0.0%)
Factors Behind Changes in Business Performance

The Life Science AI business posted higher revenue due to the accumulation of co-creation project contracts and DDAIF Innovation Bridge contracts, as well as one-time revenue related to AI medical device development. However, the business recorded an operating loss due to growth investments, including the expansion of its research staff. The Risk Management business posted lower revenue due to the cancellation of a major customer contract, delays in winning new projects, a decline in e-discovery projects, cancellations of private-sector projects, and the concentration of government projects in the second half. The DX business posted higher revenue and profit due to increased sales.

Disclosure regarding the going concern assumption

There are no applicable matters.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 1 company (FRONTEO Korea,Inc.)
Material subsequent eventsThere are no applicable matters.
Impairment loss¥12.863 million: ¥6.504 million in internally used software in the Risk Management business and ¥6.358 million in prepaid expenses related to discontinued services.
Breakdown of extraordinary income (loss)Extraordinary income Gain on reversal of stock acquisition rights 5,607 Thousand yen, Gain on sale of shares in affiliates 47,044 Thousand yen, Gain on reversal of foreign currency translation adjustment 13,380 Thousand yen / Extraordinary loss Impairment loss 12,863 Thousand yen, Loss on disposal of property, plant and equipment 2,406 Thousand yen, Restructuring Costs 56,313 Thousand yen
Depreciation and amortization224,236 Thousand yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End39,412,362
Treasury Shares at Period-End230,859
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 April 2026 to 30 September 2026
Net Sales¥3,292 million (YoY -2.5%)
Operating profit¥-244 million
Ordinary income¥-229 million
Profit attributable to owners of the parent¥-186 million
Net income per share-¥4.77
Equity ratioEnd of the current fiscal period 39.5 / End of previous period 39.7
Total assets¥8,761 million
Net assets¥3,645 million
Cash flows from operating activities-135,573 Thousand yen
Cash flows from investing activities-482,966 Thousand yen
Cash flows from financing activities152,613 Thousand yen
Cash and cash equivalents at end of period1,257,541 Thousand yen
Full-year earnings forecastNet Sales ¥7,600 million (YoY -0.6%) / Operating profit ¥300 million (YoY -59.4%) / Ordinary income ¥250 million (YoY -63.0%) / Net income ¥150 million (YoY -72.4%)
Annual Dividend Forecast0 Yen → 0 Yen(0.0%)
Segment revenueLife Science AI business 384,496 Thousand yen (YoY +40.3%), Risk management business 1,539,456 Thousand yen (YoY -24.2%), DX business 1,429,219 Thousand yen (YoY +32.7%)
Segment profitLife Science AI business -149,455 Thousand yen, Risk management business -114,388 Thousand yen, DX business 68,934 Thousand yen (YoY +48.8%)
Depreciation and amortization224,236 Thousand yen
Impairment loss¥12.863 million: ¥6.504 million in internally used software in the Risk Management business and ¥6.358 million in prepaid expenses related to discontinued services.
Breakdown of extraordinary income (loss)Extraordinary income Gain on reversal of stock acquisition rights 5,607 Thousand yen, Gain on sale of shares in affiliates 47,044 Thousand yen, Gain on reversal of foreign currency translation adjustment 13,380 Thousand yen / Extraordinary loss Impairment loss 12,863 Thousand yen, Loss on disposal of property, plant and equipment 2,406 Thousand yen, Restructuring Costs 56,313 Thousand yen
Disclosure regarding the going concern assumptionThere are no applicable matters.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew 0 companies / Excluded 1 company (FRONTEO Korea,Inc.)
Material subsequent eventsThere are no applicable matters.
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End39,412,362
Treasury Shares at Period-End230,859
Factors Behind Changes in Business PerformanceThe Life Science AI business posted higher revenue due to the accumulation of co-creation project contracts and DDAIF Innovation Bridge contracts, as well as one-time revenue related to AI medical device development. However, the business recorded an operating loss due to growth investments, including the expansion of its research staff. The Risk Management business posted lower revenue due to the cancellation of a major customer contract, delays in winning new projects, a decline in e-discovery projects, cancellations of private-sector projects, and the concentration of government projects in the second half. The DX business posted higher revenue and profit due to increased sales.
Items this document does not state (6)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlog

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Life Science AI business posted higher revenue as projects accumulated, but recorded an operating loss due to growth investments, including the expansion of its research staff. The Risk Management business posted lower revenue and an operating loss due to the cancellation of a major customer contract, delays in winning new projects, a decline in e-discovery projects, cancellations of private-sector projects, and the concentration of government projects in the second half. The DX business posted higher revenue and profit due to increased sales.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 (Japanese GAAP) (Consolidated) | FRONTEO,Inc. (2158) timely disclosure | Komori